DAIC

APRIL 5, 2024

With the addition of Shockwave, Johnson & Johnson will expand its MedTech cardiovascular portfolio into two of the highest-growth, innovation-oriented segments of cardiovascular intervention – coronary artery disease (CAD) and peripheral artery disease (PAD). The Reducer System has a growing commercial presence.

Cardiovascular Interventions 105

Cardiovascular Interventions Technology Innovation Angina 105

Frontiers in Cardiovascular Medicine

FEBRUARY 27, 2024

Patients with a new or recurrent episode of ASCVD (angina, acute myocardial infarction, transient ischemic attack, stroke, or peripheral arterial disease) between 1-Jan-2017 and 31-Dec-2018 were included.

Cardiovascular Disease 45

Cardiovascular Disease Peripheral Arterial Disease Drug Costs Myocardial Infarction 45

DAIC

JANUARY 23, 2024

21-23 hsCRP is nonspecific inflammatory marker and an acute phase reactant that predicts the likelihood of a heart attack, stroke, peripheral artery disease and sudden cardiac death among healthy individuals with no history of CV disease, and recurrent events and death in patients with known ASCVD.22

Cardiovascular Disease 111

Cardiovascular Disease Heart Attack Heart attacks Coronary Artery Disease 111

Dr. Anish Koka

MAY 16, 2023

Not surprisingly, a dataset of coronary angiograms and chest pain syndromes showed that the more classic the chest pain syndrome was, the higher the likelihood that angiographic coronary disease was present. Atypical angina is classified as having any two of the three symptoms, and non-anginal pain any one of the three symptoms.

Chest Pain 52

Chest Pain Coronary Artery Disease Cancer Heart Attack 52